THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [12.29] ID: TIP-MED-000261

Silver Sulfadiazine (1% Topical Burn Antimicrobial Cream)

Active Ingredient / Scientific Identity: Silver Sulfadiazine • Class: Topical Heavy-Metal / Sulfonamide Burn Antimicrobial

⚖️ Compare Profile
Generic / Entity NameSilver Sulfadiazine (1% Topical Burn Antimicrobial Cream) ([12.29])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassTopical Heavy-Metal / Sulfonamide Burn Antimicrobial
Available Dosage FormsSterile Topical Cream: 1% w/w (20 g, 50 g, 250 g, 500 g tubes/jars; some Indian brands combine Chlorhexidine 0
Regulatory ClassificationSchedule H Prescription Drug (To be sold by retail on the prescription of a Registere
Key Warning & Review DateRenal: When applied to extensive full-thickness burns (>20-30% BSA), significant systemic absorption of sulfadiazine occurs—m
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug (To be sold by retail o✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Silver Sulfadiazine (1% Topical Burn Antimicrobial Cream) (TIP-MED-000261, Reference Code [12.29]) is classified under Dermatological & Topical Antiseptic Preparations (Ch 12) as a Topical Heavy-Metal / Sulfonamide Burn Antimicrobial. Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 12 [12.29], p. 169): Silverex, Burnol-SSD, Silvirin — Strengths & Dosage Forms: Sterile Topical Cream: 1% w/w (20 g, 50 g, 250 g, 500 g tubes/jars; some Indian brands combine Chlorhexidine 0.2%).
Representative Indian Market Examples (Edition 2.7 Ch 12 [12.29], p. 169): Silverex, Burnol-SSD, Silvirin — Strengths & Dosage Forms: Sterile Topical Cream: 1% w/w (20 g, 50 g, 250 g, 500 g tubes/jars; some Indian brands combine Chlorhexidine 0.2%).
Dosage Forms & Available Strengths:
Sterile Topical Cream: 1% w/w (20 g, 50 g, 250 g, 500 g tubes/jars; some Indian brands combine Chlorhexidine 0.2%).
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Slowly releases bactericidal silver ions (Ag+) that bind bacterial DNA and cell membranes, combined with sulfadiazine competitive inhibition of bacterial dihydropteroate synthase; active against Pseudomonas aeruginosa, Staphylococcus aureus, and Candida.

4. Therapeutic Indications & Evidence-Supported Uses

  • Prevention and treatment of wound sepsis in second- and third-degree thermal burns

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Adult: After cleansing and debriding burn wound, apply a sterile 3–5 mm thick layer over the burn surface 1–2 times daily using a sterile gloved hand or spatula. • Paediatric: Children >2 months: Apply 3-5 mm layer 1-2 times daily. CONTRAINDICATED in preterm infants and neonates <2 months.

Administration & Meal Timing: See Administration & Counselling below. | Standard clinical schedule per indication.

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal: When applied to extensive full-thickness burns (>20-30% BSA), significant systemic absorption of sulfadiazine occurs—monitor renal function and maintain high urine output to prevent crystalluria. • Hepatic: Caution on extensive burns in severe hepatic impairment.
Elimination & Renal Adjustment:
Renal: When applied to extensive full-thickness burns (>20-30% BSA), significant systemic absorption of sulfadiazine occurs—monitor renal function and maintain high urine output to prevent crystalluria. • Hepatic: Caution on extensive burns in severe hepatic impairment.
Hepatic Impairment Considerations:
Renal: When applied to extensive full-thickness burns (>20-30% BSA), significant systemic absorption of sulfadiazine occurs—monitor renal function and maintain high urine output to prevent crystalluria. • Hepatic: Caution on extensive burns in severe hepatic impairment.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Contraindications: Term pregnancy at or near labour, preterm infants, and neonates <2 months of age (sulfonamide displaces bilirubin from albumin -> kernicterus); known sulfonamide hypersensitivity; severe G6PD deficiency (haemolysis risk on large burns). • Precautions: Transient leukopenia/neutropenia commonly occurs on Days 2–4 of extensive burn application (usually recovers spontaneously despite continued therapy); avoid applying to the face (risk of grey argyria pigmentation on sun exposure); delays epithelialisation if continued after eschar separation.

Key Clinical Precautions: Renal: When applied to extensive full-thickness burns (>20-30% BSA), significant systemic absorption of sulfadiazine occurs—monitor renal function and maintain high urine output to prevent crystalluria. • Hepatic: Caution on extensive burns in severe hepatic impairment.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Transient local burning, brownish-grey pseudoeschar discolouration of wound bed, reversible leukopenia (Days 2-4).
  • Stevens-Johnson syndrome / TEN (sulfonamide component), haemolytic anaemia in G6PD deficiency, argyria (prolonged large-area use), kernicterus in neonates.
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Topical proteolytic enzymatic debriding agents (Collagenase, Papain-Urea) -> silver ions inactivate enzymes; Povidone-iodine -> chemical incompatibility

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: Keep burned area covered with a 3-5 mm layer of cream at all times (reapply to any area rubbed off by dressings); yellowish-grey film on wound surface is normal reaction of silver with wound fluid, not pus.
  • Meal & Clock Timing Instruction: See Administration & Counselling below. (Standard clinical schedule per indication.)
  • Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
  • Geriatric Dispensing Pearl: Schedule: Schedule H | NLEM 2022: Yes | Compendia: IP 2026 / NFI 7th Ed 2026 / NLEM 2022 / CDSCO Schedule H / BNF 90th Ed

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Sterile Topical Cream: 1% w/w (20 g, 50 g, 250 g, 500 g tubes/jars; some Indian brands combine Chlorhexidine 0.2%).

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 12 [12.29] (p. 169)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.